Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Crystal Bridge Enterprises Inc. (V:CRYS.P)

Business Focus: N/A

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for CRYS within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Dec 04, 2020 16:27 ET
Crystal Bridge Announces Receipt by Alpha Cognition of Japanese Patent for Alzheimer Drug Alpha-1062 and Announces Private Placement Updates
Vancouver, British Columbia--(Newsfile Corp. - December 4, 2020) - Crystal Bridge Enterprises Inc. (TSXV: CRYS.P) ("Crystal Bridge", or the "Company") is pleased to announce that Alpha Cognition Inc. ("ACI"), has received confirmation of a patent being granted in Japan for Alpha 1062 drug being developed for use in the treatment of neurodegenerative diseases, including Alzheimer's disease. This patent grant further demonstrates the value of Alpha-1062's patent family globally.
Read full article
Oct 28, 2020 07:30 ET
Crystal Bridge Enters into Arrangement Agreement with Alpha Cognition, Announces up to $13 Million Private Placement
Vancouver, British Columbia--(Newsfile Corp. - October 28, 2020) - Crystal Bridge Enterprises Inc. (TSXV: CRYS) (the "Company") a capital pool company ("CPC") as defined under Policy 2.4 - Capital Pool Companies ("Policy 2.4") of the TSX Venture Exchange (the "Exchange"), is pleased to announce that, further to its news release dated July 14, 2020, the Company and Alpha Cognition Inc. ("ACI"), a private company incorporated under the Business Corporations Act (British Columbia), have entered into an arrangement agreement dated October 27, 2020 (the "Arrangement Agreement"), pursuant to which the Company will acquire all of the issued and outstanding securities of ACI (the "Transaction").
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
--
--
--
Price to Sales - TTM
--
--
--
Price to Book - most recent quarter
--
--
--
Price to Cash Flow per share - TTM
--
--
--
Price to Free Cash Flow per share - TTM
--
--
--
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Dec 31, 196900
Dec 31, 196900
Dec 31, 196900
See Short Report

Business Summary

Sector:  N/A Industry:  N/A

See business summary

 

Twitter

Search (past week) for $CRYS.P

  • No tweets found